Two chemotherapy combinations for left-sided colorectal cancer
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial compares two different chemotherapy combinations, each paired with an immunotherapy drug, as the first treatment for left-sided colorectal cancer that has spread. The goal is to see which combination works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be in the left side of the colon or the rectum, and it must have spread to other parts of the body.
- Tumor tissue tests must show no changes (mutations) in the KRAS, NRAS, or BRAF genes.
- You should not have had prior chemotherapy or other drug therapy for advanced colorectal cancer.
- You must have at least one measurable tumor and be generally healthy enough for treatment (good daily activity level).
- If you are of childbearing age, you must agree to use reliable contraception during the study and for 5 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a combination of a new immunotherapy drug (QL1706) with chemotherapy and either cetuximab or bevacizumab for people with colorectal cancer that has spread to the liver and can potentially be removed by surgery. The goal is to shrink the tumors before surgery, making them easier to remove.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This study compares two different combinations of chemotherapy plus a targeted therapy called cetuximab as a first treatment for a specific type of advanced colorectal cancer. The goal is to see which combination works better and has fewer side effects.
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
This trial compares two standard chemotherapy combinations for people whose colorectal cancer has spread and cannot be removed with surgery. Depending on certain genetic markers, participants also receive either bevacizumab or cetuximab to help the treatment work better.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.